TSLA
Tesla
-- 421.060 PLTR
Palantir
-- 80.550 NVDA
NVIDIA
-- 134.700 AMD
Advanced Micro Devices
-- 119.210 OXY
Occidental Petroleum
-- 47.130 
NEWS
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg monotherapy at day 84 with statistical significance (p<0.001) --
-- Obicetrapib and ezetimibe fixed-dose combination observed to lower LDL-C by approximately 50% at day 84, compared to placebo, with over 70% of patients achieving LDL-C levels below 55 mg/dL --
-- Data supports global regulatory filings of the obicetrapib 10 mg and ezetimibe 10 mg fixed-dose combination --
-- Observed to be well tolerated with safety results in line with prior studies --
-- NewAmsterdam to host conference call today at 8:00 a.m. ET -
-- Obicetrapib and ezetimibe fixed-dose combination observed to lower LDL-C by approximately 50% at day 84, compared to placebo, with over 70% of patients achieving LDL-C levels below 55 mg/dL --
-- Data supports global regulatory filings of the obicetrapib 10 mg and ezetimibe 10 mg fixed-dose combination --
-- Observed to be well tolerated with safety results in line with prior studies --
-- NewAmsterdam to host conference call today at 8:00 a.m. ET -
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment